Transcend Therapeutics is discovering and developing psychedelic medicines for neuropsychiatry. The largest cause of disability worldwide is now neuropsychiatric illnesses with 1 billion people currently suffering; however there is little investment and innovation in developing new treatments. Transcend aims to rectify this problem by identifying psychedelics with clinical and nonclinical safety profiles and prioritizing those with therapeutic effect. Patient access enables Transcend to then verify treatments and identify those with shorter treatment durations, minimal patient inebriation and fewer undesirable effects compared to traditional psychedelics. Transcend’s lead product has demonstrated >85% response rates in patients with depression and PTSD.